Papilomavírus humano e neoplasia cervical;Human papillomavirus and cervical neoplasia

Cadernos de Saude Publica

Volumn 25, Issue 5, 2009, Pages 953-964

  da Rosa, Maria Inês ^a   Medeiros, Lídia Rosi ^b   Rosa, Daniela Dornelles ^b   Bozzeti, Mary Clarisse ^b   Silva, Fábio Rosa ^a   Silva, Bruno Rosa ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cervical intraepithelial neoplasia; DNA viruses; Papillomavirus infections

Indexed keywords

WART VIRUS VACCINE;

CLASSIFICATION; FEMALE; HUMAN; PAPILLOMA VIRUS; PREVALENCE; REVIEW; RISK FACTOR; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 69249222754     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/s0102-311x2009000500002     Document Type: Review

References (112)

1. Parkim DM. Global cancer statistics in year 2000. Lancet Oncol 2001; 2:533-43.
2. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44:7-26.
3. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92:690-8.
4. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983; 80:3812-5.
5. The Nobel Foundation. 2008 Nobel Prize winner "for his discovery of human papilloma viruses causing cervical cancer". http://nobelprize.org (acessado em 06/Out/2008).
6. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. BMJ 1986; 293: 659-64.
7. Duarte-Franco E, Franco EL. Cancer of the uterine cervix. BMC Womens Health 2004; 4 Suppl 1:S13.
8. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papilloma-virus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer world-wide. J Pathol 1999; 189:12-9.
10. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002; 3:11-6.
11. International Committee on Taxonomy of Viruses. ICTV approved virus orders, families and genera. http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/index.htm (acessado em 24/Out/2008).
12. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, et al. Arrangement of L2 within the papillomavirus capsid. J Virol 2008; 82:5190-7.
13. Southern SA, Herrington CS. Molecular events in uterine cervical cancer. Sex Transm Infect 1998; 74:101-9.
14. Finnen RL, Erickson KD, Chen XS, Garcea RL, Interactions between papillomavirus L1 and L2 capsid proteins. J Virol 2003; 77:1410-26.
15. Florin L, Sapp C, Streeck RE, Sapp M. Assembly and translocation of papillomavirus capsid proteins. J Virol 2002; 76:10009-14.
16. Christensen ND, Höopfl R, Diangelon SL, Cladel NM, Patrick SD, Welsh PA, et al. Assembled baculovirus - expressed human papillomavirus type 11 L1 capsid protein virus - like - particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75:2271-6.
17. Muñoz N, Bosch FX, Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
18. Sanclemente G, Gill DK. Human papillomavirus molecular biology and pathogenesis. J Eur Acad Dermatol Venereol 2002; 16:231-40.
19. Kaufman RH, Adam E, Vonka V. Human papilloma-virus infection and cervical carcinoma. Clin Obstet Gynecol 2000; 43:363-80.
20. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16:1-17.
21. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A 1995; 92:1654-8.
22. Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmuller L, Deppert W. Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 1999; 18: 7706-17.
23. Dey D, Dahl J, Cho S, Benjamin TL. Induction and bypass of p53 during productive infection by polyomavirus. J Virol 2002; 76:9526-32.
24. Alunni-Fabroni M, Littlewood T, Deleu L, Caldeira S, Giarrè M, DellÓrco M, et al. Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts. Oncogene 2000; 19:2277-85.
25. Liu X, Clements A, Zhao K, Marmorstein R. Structure of human papillomavirus E7 oncoprotein and its mechanisms for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 2006; 281:578-86.
26. Kastan MB, Bartc J. Cell cycle checkpoints and cancer. Nature 2004; 432:316-23.
27. Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci 2004; 50:9-19.
28. Scheffner M, Whitaker NJ. Human papillomavirus induced carcinogenesis and the ubiquitin-protea-some system. Semin Cancer Biol 2003; 13:59-67.
29. Thomas M, Banks L. Human pappillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 1999; 80:1513-7.
30. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type16. Nature 1996; 996:79-82.
31. Veldman T, Liu X, Yuan H, Schlege L R. Human pappillomavirus E6 and Myc proteins associate in vivo and bind to a cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci U S A 2003; 100:8211-6.
32. Rosa MI, Medeiros LR, Bozzetti MC, Fachel J, Wendland E, Zanini RR, et al. Accuracy of telomerase in cervical lesions: a systematic review. Int J Gynecol Cancer 2007; 17:1205-14.
33. Araujo-Souza PS, Maciag PC, Ribeiro KB, Petzl-Erler ML, Franco EL, Villa LL. Interaction between polymorphisms of the human leukocyte antigen and HPV-16 variants on the risk of invasive cervical cancer. BMC Cancer 2008; 8:246.
34. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8.
35. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996; 23:333-41.
36. Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993; 53:919-23.
37. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-74.
38. Muñoz N, Bosch FX, Sanjosé S, Tafur L, Izarzugaza I, Gili M, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992; 52:743-9.
39. Giuliano AR, Papenfuss MR, Denman CA, Zapien JG, Abrahamsen M, Hunter JB. Human papilloma-virus prevalence at the USA-Mexico border among women 40 years of age and older. Int J STD AIDS 2005; 16:247-51.
40. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-8.
41. Lorenzato F, Ho L, Terry G, Singer A, Santos LC, De Lucena-Batista R, et al. The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil). Int J Gynecol Cancer 2000; 10:143-50.
42. Rabelo-Santos SH, Zeferino L, Villa LL, Sobrinho JP, Amaral RG, Magalhães AV. Human papilloma-virus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiânia, Brazil. Mem Inst Oswaldo Cruz 2003; 98:181-4.
43. Cavalcanti SM, Zardo LG, Passos MR, Oliveira LH. Epidemiological aspects of human papillomavirus infection and cervical cancer in Brazil. J Infect 2000; 40:80-7.
44. Noronha V, Mello W, Villa L, Brito A, Macedo R, Bisi F, et al. Human papillomavirus associated with uterine cervix lesions. Rev Soc Bras Med Trop 1999; 32:235-40.
45. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
46. Wright Jr. TC, Ellerbrock TV, Chiasson MA, Van Devanter N, Sun XW. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591-7.
47. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001; 164:1017-25.
48. Wellings K, Field J, Johnson A, Wadsworth J. Sexual behaviour in Britain - The National Survey of Sexual Attitudes and Lifestyles. London: Penguin Books; 1994.
49. Ford K, Reed B, Wirawan D, Muliawan P, Sutarga M, Gregoire L. The Bali STD/AIDS Study: human papillomavirus infection among female sex workers. Int J STD AIDS 2003; 14:681-7.
50. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89:229-40.
51. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2194-8.
52. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital humam papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; (31):14-9.
53. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183:8-15.
54. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180:1415-23.
55. Bontkes HJ, de Gruijl TD, Walboomers JM, Schiller JT, Dillner J, Helmerhorst TJ, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999; 80 (Pt 2):409-17.
56. de Gruijl TD, Bontkes HJ, Walboomers JM, Stukart MJ, Doekhie FS, Remmink AJ, et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998; 58:1700-6.
57. Sedjo RL, Roe DJ, Abrahamsen M, Harris RB, Craft N, Baldwin S, et al. Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 2002; 11:876-84.
58. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106-14.
59. Giuliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MR, et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13:839-46.
60. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 Suppl 1:S16-24.
61. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995; 33:2058-63.
62. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072-9.
63. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12:186-92.
64. Lacey Jr. JV, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, et al. Oral contraceptives as risk factors for cervicar adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999; 8:1079-85.
65. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359:1085-92.
66. Smith JS, Green J, Berrington-de-Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159-67.
67. World Health Organization. Depotmedroxypro-gesterone acetate (DPMA) and cancer: memorandum from a WHO meeting. Bull World Health Organ 1993; 71:669-76.
68. Skegg DCG. Monthly combined injectable contraceptives and neoplasia. Contraception 1994; 49:435-9.
69. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000; 83:1565-72.
70. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94:1406-14.
71. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989; 70(Pt 8):2227-32.
72. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 1996; 93:2930-5.
73. Sethi S, Muller M, Schneider A, Blettner M, Smith E, Turek L, et al. Serologic response to the E4, E6, and E7 proteins of human papillomavirus type 16 in pregnant women. Am J Obstet Gynecol 1998; 178:360-4.
74. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002; 252:206-24.
75. Haverkos HW, Soon G, Steckley SL, Pickworth W. Cigarette smoking and cervical cancer: part I: a meta-analysis. Biomed Pharmacother 2003; 57: 67-77.
76. Trimble CL, Genkinger JM, Burke AE, Hoffman SC, Helzlsouer KJ, Diener-West M, et al. Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol 2005; 105:174-81.
77. Wu MT, Lee LH, Ho CK, Liu CL, Wu TN, Wu SC, et al. Lifetime exposure to environmental tobacco smoke and cervical intraepithelial neoplasms among nonsmoking Taiwanese women. Arch Environ Health 2003; 58:353-9.
78. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001; 84:1219-26.
79. Olsen AO, Dillner J, Skrondal A, Magnus P. Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology 1998; 9:346-9.
80. Prokopczyk B, Cox JE, Hoffmann D, Waggoner E. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 1997; 89:868-73.
81. Poppe WA, Ide PS, Drijkoningen MP, Lauweryns JM, Van Assche FA. Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study. Gynecol Obstet Invest 1995; 39:34-8.
82. Barton SE, Maddox PH, Jenkins D, Edwards R, Cuzick J, Singer A. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet 1988; 2:652-4.
83. Byers T, Perry G. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu Rev Nutr 1992; 12:139-59.
84. Van Poppel G, van den Berg H. Vitamins and cancer. Cancer Lett 1997; 114:195-202.
85. Doll R. The Pierre Denoix Memorial Lecture: nature and nurture in the control of cancer. Eur J Cancer 1999; 35:16-23.
86. Olson JA. Provitamin A function of carotenoids: the conversion of beta-carotene into vitamin A. J Nutr 1989; 119:105-8.
87. Krinsky NI. Carotenoids as antioxidants. Nutrition 2001; 17:815-7.
88. Niki E, Noguchi N, Tsuchihashi H, Gotoh N. Inter-action among vitamin C, vitamin E, and beta-carotene. Am J Clin Nutr 1995; 62(6 Suppl):1322S-6S.
89. Castle PE, Giuliano AR. Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients - assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 2003; (31):29-34.
90. Palan PR, Mikhail MS, Goldberg GL, Basu J, Runowicz CD, Romney SL. Plasma levels of beta-carotene, lycopene, canthaxanthin, retinol, and alpha - and tau-tocopherol in cervical intraepithelial neoplasia and cancer. Clin Cancer Res 1996; 2:181-5.
91. Potischman N, Herrero R, Brinton LA, Reeves WC, Stacewicz-Sapuntzakis M, Jones CJ, et al. A case-control study of nutrient status and invasive cervical cancer. II. Serologic indicators. Am J Epidemiol 1991; 134:1347-55.
92. Batieha AM, Armenian HK, Norkus EP, Morris JS, Spate VE, Comstock GW. Serum micronutrients and the subsequent risk of cervical cancer in a population-based nested case-control study. Cancer Epidemiol Biomarkers Prev 1993; 2:335-9.
93. Kwasniewska A, Tukendorf A, Semczuk M. Content of alpha-tocopherol in blood serum of human Papillomavirus-infected women with cervical dysplasias. Nutr Cancer 1997; 28:248-51.
94. Knekt P. Serum vitamin E level and risk of female cancers. Int J Epidemiol 1988; 17:281-6.
95. Giuliano AR, Papenfuss M, Nour M, Canfield LM, Schneider A, Hatch K. Antioxidant nutrients: associations with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 1997; 6:917-23.
96. Cerutti PA. Oxidant stress and carcinogenesis. Eur J Clin Invest 1991; 21:1-5.
97. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. IARC multicentric case-control study. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111:431-9.
98. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285:47-51.
99. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overex-pressed in human cervical cancer. Clin Cancer Res 2001; 7:429-34.
100. Palefsky JM, Holly EA. Chapter 6: imunossupression and co-infection with HIV. J Natl Cancer Inst Monogr 2003; (31):41-6.
101. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-86.
102. Conti M, Agarossi A, Parazzini F, Muggiasca ML, Boschini A, Negri E, et al. HPV, HIV infection, and risk of cervical intraepithelial neoplasia in former intravenous drug abusers. Gynecol Oncol 1993; 49:344-8.
103. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminate and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108-13.
104. Fordyce EJ, Wang Z, Kahn AR, Gallagher BK, Merlos I, Ly S, et al. Risk of cancer among women with AIDS in New York City. AIDS Public Policy J 2000; 15:95-104.
105. Serraino D, Dal Maso L, La Vecchia C, Franceschi S. Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002; 16:781-6.
106. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167-73.
107. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
108. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
109. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693-702.
110. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369:1861-8.
111. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24:5571-83.
112. Harper DM. Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 2008; 5:313-24.